• SOPHiA Genetics, AstraZeneca Team Up To Expand Liquid Biopsy Testing To 20 New Locations Globally

    Source: NASDAQ US Markets / 10 Sep 2024 11:30:45   America/New_York

    (RTTNews) - SOPHiA Genetics SA (SOPH), Tuesday announced a partnership with AstraZeneca (AZN) to further enhance the deployment of liquid biopsy testing MSK-ACCESS powered with SOPHiA DDM to 20 locations worldwide within the next one year. https://www.nasdaq.com/articles/sophia-genetics-astrazeneca-team-expand-liquid-biopsy-testing-20-new-locations-globally
Share on,